Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 33.50
Bid: 32.00
Ask: 35.00
Change: -1.50 (-4.29%)
Spread: 3.00 (9.375%)
Open: 35.00
High: 35.00
Low: 33.50
Prev. Close: 35.00
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Utah Lab Facility Achieves ISO 13485 Certification

27 Apr 2020 07:00

RNS Number : 8794K
Renalytix AI PLC
27 April 2020
 

Renalytix AI plc

("RenalytixAI", the "Company" or the "Group")

 Utah Commercial Laboratory Facility Achieves ISO 13485 Certification

 

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that it has received ISO 13485:2016 certification for its development and commercial laboratory operations facility in Salt Lake City, Utah. The Company's rigorous development, validation and laboratory testing processes have been independently assessed as being carried out in accordance with ISO 13485, representing a 'high water' benchmark of excellence for its lead product KidneyIntelXTM as well as future products.

 

The KidneyintelX platform incorporates proprietary biomarker measurements, personal health data integration, machine learning algorithms and a comprehensive software solution and therefore requires robust processes and quality control to ensure the highest level of product quality, data integrity and information security. The adoption of this globally recognized international standard for quality management systems provides a best practice and regulatory compliant framework to achieve these objectives.

 

ISO 13485:2016 is an internationally agreed upon standard that sets out the requirements for a quality management system specific to the medical device industry. RenalytixAI has developed a multi-faceted quality system incorporating not only the requirements of this standard but all other applicable quality standards and regulations. As a legal manufacturer of in vitro diagnostics products and laboratory services provider for KidneyIntelX and future products, RenalytixAI currently must comply with the Clinical Laboratory Improvement Amendments (CLIA), US 21CFR820 of the FDA (cGMP) and New York State Department of Health (NYS-DOH). It is for this reason that the implementation of a robust and adaptable Quality Management framework that meets or exceeds all regulatory requirements was a strategic decision of the Board made from pre-inception business planning.

 

"The investment we have made in a comprehensive quality management system not only puts us in a favorable position with regulatory agencies and payors, it provides us a competitive advantage to collaborate with pharmaceutical partners and large health systems. This certification also positions us for accelerated international market access for KidneyIntelX. More importantly, it provides ordering physicians and patients confidence in the results they are receiving," said Sally Bowden, Chief Business Officer/Head of Quality and Regulatory Affairs at RenalytixAI.

 

As part of ongoing commercialization activities, RenalytixAI is implementing processes and controls to comply with the voluntary ISO/IEC 27001:2013 which specifies the requirements for establishing, implementing, maintaining and continually improving an information security management system. This includes requirements for the assessment and treatment of information security risks tailored to the needs of the organization and, importantly, the needs of the Group's customers and patients.

 

For further information, please contact:

 

Renalytix AI plc 

www.renalytixai.com

James McCullough, CEO

Via Walbrook PR

Stifel (Nominated Adviser & Joint Broker)

Tel: 020 7710 7600

Alex Price / Jonathan Senior / Ben Maddison

N+1 Singer (Joint Broker)

Tel: 020 7496 3000

Aubrey Powell / George Tzimas (Corporate Finance)

Tom Salvesen / Mia Gardner (Corporate Broking)

Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

 

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

About Kidney Disease 

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control estimates there that 15% of United States adults or 37 million people currently have chronic kidney disease. It is reported that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day 13 patients die in the United States while waiting for a kidney transplant.

 

* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

 

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

For more information, visit renalytixai.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABDGDSCBDDGGL
Date   Source Headline
28th Mar 20245:07 pmRNSForm 8.3 - Renalytix plc
28th Mar 20242:52 pmRNSHolding(s) in Company
28th Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc
27th Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc
26th Mar 20243:14 pmRNSHolding(s) in Company
26th Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc
26th Mar 20247:54 amGNWForm 8.5 (EPT/RI) - Renalytix plc
25th Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc
22nd Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc
22nd Mar 20248:37 amGNWForm 8.5 (EPT/RI) - Renalytix plc
21st Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc
21st Mar 20247:00 amRNSForm 8.3 - Renalytix Plc
21st Mar 20246:45 amGNWForm 8.5 (EPT/RI) - Renalytix Plc
20th Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc
20th Mar 20247:29 amGNWForm 8.5 (EPT/RI) - Renalytix plc
19th Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc
18th Mar 20244:18 pmRNSForm 8.3 - Renalytix Plc - Replacement
18th Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc
18th Mar 202411:54 amRNSForm 8.3 - Renalytix Plc
18th Mar 202410:27 amRNSForm 8.3 - Renalytix Plc
18th Mar 20247:56 amGNWForm 8.5 (EPT/RI) - Renalytix Plc
15th Mar 20243:20 pmPRNForm 8.3 - Renalytix Plc
15th Mar 20243:02 pmRNSForm 8.3 - Renalytix PLC
15th Mar 20242:55 pmRNSForm 8.3 - Renalytix plc
15th Mar 20242:42 pmRNSForm 8.3 - Renalytix plc
15th Mar 20241:36 pmRNSForm 8.3 - Renalytix PLC
15th Mar 202412:05 pmRNSForm 8 (DD) - Renalytix Plc
15th Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc
15th Mar 202410:23 amRNSForm 8.3 - Renalytix PLC - Replacement
15th Mar 20247:27 amGNWForm 8.5 (EPT/RI) - Renalytix plc
15th Mar 20247:00 amRNSRule 2.9 announcement
14th Mar 20244:38 pmPRNForm 8.3 - Renalytix Plc
14th Mar 20244:03 pmPRNForm 8.3 - Renalytix Plc
14th Mar 20243:38 pmRNSForm 8 (DD) - Renalytix Plc
14th Mar 202412:02 pmRNSForm 8 (OPD)
14th Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc
14th Mar 202410:42 amRNSAmendment Form 8.5 (EPT/RI) - Renalytix plc
14th Mar 20247:32 amGNWForm 8.5 (EPT/RI) - Renalytix Plc
14th Mar 20247:00 amRNSKidneyIntelXâ„¢ included in KDIGO 2024 Guideline
13th Mar 20247:24 pmPRNForm 8.3 - Renalytix Plc
13th Mar 20246:14 pmRNSForm 8.3 - RENALYTIX PLC
13th Mar 20243:22 pmPRNForm 8.3 - Renalytix Plc
13th Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc
13th Mar 20247:43 amGNWForm 8.5 (EPT/RI) - Renalytix plc
12th Mar 20243:31 pmRNSSuccessful completion of upsized $12m placing
12th Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc
12th Mar 20247:59 amGNWForm 8.5 (EPT/RI) - Renalytix plc
12th Mar 20247:00 amRNSLaunch of equity placing of approximately US$10m
11th Mar 20245:24 pmRNSForm 8.3 - Renalytix Plc
11th Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.